Pfizer Therachonを買収、TA-46の権利獲得 / Pfizer Acquires Therachon and rights with TA-46

Pfizer Therachonを買収、TA-46の権利獲得 / Pfizer Acquires Therachon and rights with TA-46




2019年5月9日現在、フェーズ2を想定したMeasurement Studyは日本の施設での予定は確認できませんが、本リリースを契機とした今後の展開に期待します。


We have some news regarding Therachon’s treatment program of achondroplasia. Please see the link to the press release.

Pfizer will acquire Therachon and, with it, all rights associated with the sFGFR3 development programme for achondroplasia. This includes our lead achondroplasia asset, TA-46, which is due to enter Phase II development later in 2019.

Accourding to Therachon, “Pfizer will be able to accelerate the development of our FGFR therapeutics to ultimately provide access for more patients and expedite our vision of addressing the broad complications suffered by children living with achondroplasia.”

As of May 9, 2019, the Measurement Study for Phase 2 can not be confirmed for plans at facilities in Japan, but we look forward to future developments triggered by this release.






-About TA-46

TA-46 is an investigational, soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) decoy, a mechanism of action that is believed to normalize the overactive FGFR3 signaling pathways that underlie bone development abnormalities associated with achondroplasia. Therachon is developing TA-46 as a weekly subcutaneous injection for children and adolescents living with the condition. TA-46 has completed Phase 1 and has received Orphan Drug Designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).



Get every new post on this blog delivered to your Inbox.

Join other followers: